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ABSTRACT 
  
The aim of this study was to extend the age range of the Infant Gross Motor 
Screening Test (IGMST) to make it appropriate for use in infants infected with HIV 
from birth to five months. 
 
Previously completed Bayley Scales on Infant and Toddler Development (3rd Version) 
(BSID III) assessments, from two 2013 physiotherapy masters studies completed 
through the University of the Witwatersrand, were used to compile 
neurodevelopmental scores achieved by infants infected with HIV. These scores 
were used to select developmentally appropriate items for inclusion in the new 
section of the IGMST. These items were statistically tested against the original BSID 
III scores using the Pearson correlation coefficient. Following statistical testing, 
content validity of the new section of the IGMST was established with an expert 
panel using a modified nominal group technique (NGT).  
 
The new section of the IGMST included two age bands; one to three months and four 
to five months. Each age band consisted of five items. Age band one to three months 
had a Pearson correlation coefficient of r =0.68 (p = 0.003) and 84% of the infants 
performed the same on both tests. Age band four to five achieved a Pearson 
correlation coefficient r = 0.71 (p = 0.0009) and 83% of infants performed the same 
on both tests.  When presented to the expert panel using a modified NGT, all items 
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and questions raised were accepted by 100% after appropriate adjustments were 
made. 
 
In conclusion, the new section of the IGMST has been developed for infants from one 
to five months and the content validity has been established during the course of this 
study. The new section must still undergo further validity and reliability testing before 
it can be used clinically.  
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CHAPTER ONE 
1 INTRODUCTION 
1.1 Introduction 
Sub-Saharan Africa still faces challenges with the management of the Human 
Immunodeficiency Virus (HIV) epidemic despite the improved availability of 
antiretrovirals (ARVs). HIV has infected 36.7million people worldwide with Sub-
Saharan Africa having 19.4million of those living with HIV. Women account for more 
than half of this number (59%) (UNAIDS, 2017). The higher percentage of women 
infected translates to a high number of children infected with HIV. Despite a decline 
in the number of infections due increased access to ARVs there were still an 
estimated 12000 new infections among children in South Africa in 2016 (UNAIDSa, 
2017), as well as 160 000 new infections amoungst children world wide (UNAIDSb, 
2017). 
 
The infection of infants is directly linked to infection among women (UNAIDS, 2016). 
Mother to child transmission (vertical transmission) can occur perinatally or in the 
neonatal period through various pathways. The rate of HIV transmission from mother 
to child has been dramatically decreased since the roll out of ARVs. South Africa has 
achieved a 90% reduction in vertical infections (UNAIDS, 2016) and transmission 
rates in Gauteng are now estimated to be around 1.7% (Gauteng Department of 
Health, 2016/2017; Sherman et al, 2017). One factor influencing transmission of HIV 
is a high maternal viral load  (Abubakar et al, 2008). Infants infected with HIV are 
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more likely to have neurodevelopmental delay and gross motor difficulties which can 
persist into childhood (Foster et al, 2006).  
 
The central nervous system (CNS) may be impacted by HIV, especially when 
children are infected perinatally (Belman, 1992). The involvement of the CNS in HIV 
is common and there is a spectrum of presentations. Neurodevelopmental delay is 
common in infants infected with HIV (Donald et al, 2014). It has been found that a 
high percentage of infants with HIV exhibit global neurodevelopmental delay 
(Whitehead et al, 2014; Hutchings & Potterton, 2013; Potterton et al, 2009; Ballieu & 
Potterton, 2008; Van Rie et al, 2007). Neurodevelopmental delay is one of the first 
indicators of the disease and may occur before any other signs (Hilburn et al, 2011).  
Numerous studies have found the gross motor aspect of neurodevelopmental delay 
to be the most affected in young infants infected with HIV (Hilburn et al, 2011; Shead 
et al, 2010; Potterton et al, 2009). It has also been found that the percentage of those 
found to have neurodevelopmental delay increases as they age (Whitehead et al, 
2014). The introduction of combination antiretroviral therapy (cART) has been found 
to reduce the progression of neurodevelopmental delay, but not improve the delay 
that was present prior to the initiation of the medication (Whitehead et al, 2014). 
 
Gross motor delay is not only noted in infants infected with HIV. It has also been 
suggested that motor delays may be the first (or most easily identified) indication of a 
global developmental delay. As infants develop, it is expected that they acquire a 
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variety of motor skills early on. Those at risk for global delay may struggle to reach 
early motor milestones (Noritz et al, 2013). 
 
It has been shown that early therapeutic intervention, for infants infected with HIV 
presenting with neurodevelopmental delay, is effective in improving their cognitive 
and motor development (Potterton et al, 2010). It is important to identify delay and 
begin treatment as early as possible, to improve a child’s developmental progress 
and allow for a better quality of life. Numerous studies have recommended that 
screening and physiotherapy intervention take place in order to improve 
developmental outcomes (Whitehead et al, 2014; Hilburn et al, 2010; Potterton et al, 
2010). 
 
Developmental screening is used to quickly identify those that may be presenting 
with neurodevelopmental delay and would benefit from a more in-depth assessment 
(Meisels & Provence, 1988).  Sub-Saharan Africa has numerous constraints that 
prevent in-depth assessment of each at risk individual. Once screened and identified 
as being at risk, infants can be referred for further assessment and, if needed, for 
therapeutic intervention. Hilburn et al. (2011) found that at the time of the study there 
was no readily available, appropriate screening tool available to use for the screening 
of infants infected with HIV. As gross motor skills are most often impacted by HIV 
infection (Hilburn et al, 2011; Shead et al, 2010; Potterton et al, 2009) it was decided 
a gross motor screening tool would be appropriate. The Infant Gross Motor 
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Screening Test (IGMST) for ages six months to eighteen months was developed and 
underwent preliminary validity and reliability testing (Hilburn et al, 2011). The original 
IGMST consists of four age bands, with five gross motor items in each. A child can 
be identified as ‘At Risk’ or ‘Satisfactory’ depending on the score they achieve. It is 
easily and freely available and simple to administer (Hilburn et al, 2011). 
 
1.2 Problem Statement 
In the South African context, there is no appropriate screening tool to detect 
developmental delay in infants infected with HIV from birth to five months. 
 
1.3 Research Question 
 What developmentally appropriate items can be selected and included in the Infant 
Gross Motor Screening Test (IGMST) to make it appropriate for use in infants 
with HIV from birth to five months? 
 
1.4 Aim of the Study 
The aim of this study is to determine which developmentally appropriate items can be 
selected and included in the IGMST to make it appropriate for use in infants infected 
with HIV from birth to five months. 
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1.5 Objectives of the Study  
• To identify gross motor items from the Bayley Scales of Infant and Toddler (3rd 
version) (BSID III) which would be suitable for inclusion in the IGMST to 
extend it for use in younger infants (birth to five months). 
• To categorise items into age group suitability (birth to three months); (four to 
five months). 
• Testing and refinement of the initial version of the new items to satisfy 
statistical criteria (Pearson’s correlation coefficient r ≥0.7). 
• To complete preliminary content validity. 
• To design and layout the new age bands in keeping with the format of the 
original IGMST. 
 
1.6 Significance of the Study 
HIV infection is still a challenge in Sub-Saharan Africa (UNAIDS, 2016). Infants 
infected with HIV have a high incidence of neurodevelopmental delay (Potterton et al, 
2009; Baillieu & Potterton, 2008).  Early physiotherapy intervention has been shown 
to improve the developmental outcomes of these individuals (Potterton et al, 2010). 
Prior to the development of the IGMST there was no appropriate developmental 
screening tool to determine if infants infected with HIV displayed gross motor delay. 
This tool is currently appropriate for use on infants from six months to 18 months 
(Hilburn et al, 2011). HIV infection is now identified at an earlier age via Polymerase 
Chain Reaction (PCR) testing and it is known which infants are at an increased risk 
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for developmental delay. Having a screening tool that can screen for delay in 
younger infants will allow further intervention to occur as early as possible and 
improve the child’s developmental outcomes and quality of life. 
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CHAPTER 2 
2 LITERATURE REVIEW  
2.1 Introduction  
This chapter will discuss the epidemiology of HIV, the entry of HIV into the CNS, the 
pathology of Human Immunodeficiency Virus Encephalopathy (HIVE) in the 
paediatric population and the link between paediatric HIV and neurodevelopment. An 
overview of developmental screening will be discussed, as well as the process used 
to develop the original IGMST.  
 
Articles discussed in this literature review were found using Science Direct, CINAHL 
EBSCO Host and Google Scholar search engines. Articles were also physically 
sourced from the Health Sciences library at the University of the Witwatersrand. 
Keywords in the literature search included HIV, HIV encephalopathy, 
neurodevelopment, CNS development, developmental surveillance and screening 
and Infant Gross Motor Screening Test. Only articles written in English were included 
in this review. There was no limit on the year of publication.  
 
2.2 Epidemiology of the HIV/AIDS Pandemic 
Globally 36.7 million people are infected with HIV.  Seventeen point eight million of 
those are women and 2.1 million of those are children. In 2010 it was estimated that 
6.1 million people in South Africa were living with HIV, it has now risen to 7.1 million. 
Girls and women are a particularly vulnerable group and in South Africa, women 
account for 59% of the HIV infected population. It is estimated that there are 257 456 
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pregnant women who are infected with HIV, and it is estimated that >95% (76% - 
>95%) of those have access to prophylaxis or treatment to prevent Mother-to-Child 
transmission (MTCT) (UNAIDS, 2016). In 2016 it was estimated that in South Africa 
there were 12 000 children between the age of 0-14 that were newly infected with 
HIV. The coverage for access to ARVs is 55%. (UNAIDS, 2017a; UNAIDS, 2017b). 
 
2.3 Vertical Transmission of HIV 
HIV infection in children is mainly as a result of mother to child transmission (MTCT) 
or vertical transmission. The infection of infants is directly linked to infection among 
women (UNAIDS, 2016). Vertical transmission can occur perinatally, at the time of 
delivery and through breast feeding, especially in mothers with a high viral load 
(Hilburn et al, 2010; Abubakar et al, 2008). The rate of HIV transmission from mother 
to child has been dramatically decreased since the roll out of ARVs. National 
transmission rates are estimated at 1.5% (National Department of Health 
2014/2015), while transmission rates in Gauteng are estimated to be at 1.7% 
(Gauteng Department of Health, 2016/2017). As the access to testing and treatment 
with cART is increasing there is a decrease in the number of HIV infected infants, this 
shows that Prevention of Mother-to-Child Transmission (PMTCT) is working 
(Sherman & Lilian, 2011).  
 
Infants infected with HIV via vertical transmission are more likely to have 
neurodevelopmental delay and gross motor difficulties that can persist into childhood 
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(Abubakar et al, 2008; Meyers et al, 2007; Foster et al, 2006). When compared to 
infants infected at a later stage, they are more likely to experience 
neurodevelopmental delay (Willen, 2006).  Neurodevelopmental delay is due to the 
invasion of the CNS by HIV. This occurs early on in the infection. These infants have 
altered development of the brain (Boisse et al, 2008; Boivin et al, 1995). This will be 
discussed further in 2.7. 
 
2.4 Infants and Children: A Priority Population 
The South African Department of Health has identified infants and children as a 
priority population. The National HIV Testing Services policy states that infants 
should be diagnosed early for all HIV-exposed infants as well as any that are 
presenting with conditions that may be as a result of HIV infection (Department of 
Health, South Africa, 2016). The HIV-related mortality rate is high if the infection is 
left untreated. More than half of HIV infected infants will die in the first two years 
without appropriate ART treatment (Marinda et al, 2007). Effective PMTCT programs 
reduce the number of HIV infections in infants exposed to HIV (Sherman et al, 2017; 
Chukwuemneka et al, 2014). Early Antiretroviral Therapy (ART) has been shown to 
reduce the risk of death by 75% when compared to deferred ART, and can reduce 
mortality and progression (Cotton et al, 2013; Welch et al, 2009; Violari et al, 2008). 
In June 2015 routine birth testing for all HIV exposed infants was included in the 
South African national guidelines (National Department of Health, 2015). 
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2.5 HIV Testing 
HIV PCR testing at birth for all HIV-exposed infants has been included in the South 
African National Guidelines since June 2015. (National Department of Health, 2015; 
Sherman, 2015). Efficient HIV testing is vital to reducing infant morbidity and mortality 
(Mazanderani et al, 2016). 
 
2.5.1 Enzyme-linked immunosorbent assay (ELISA) 
In 1985 the first assay tests developed for HIV were designed to screen blood 
products rather than diagnosing HIV. First generation HIV testing could only detect 
Immunoglobin G (IgG) antibodies six to twelve weeks after infection had occurred 
and were not always accurate and a second test was needed.  A false positive could 
be detected if the patient was pregnant, had an auto-immune disease or infections. 
By the fifth-generation assay tests for HIV, antigen and antibodies results and 
infection can be detected two weeks post-exposure (Alexander, 2016). Maternal 
antibodies circulate in an infant’s body for up to 15 months after birth and the 
recommendation is that ELISA is not done in children younger than 18 months 
(Fearon, 2005). The ELISA would identify maternal antibodies rather than the infants 
own antibodies up to 15 months (Fearon, 2005). This makes it ineffective in correctly 
identifying HIV infection in infants.  
 
2.5.2 Polymerase chain reaction (PCR) 
PCR testing for HIV amplifies viral nucleic acid so that it may be detected in the 
patient’s sample. It is a very sensitive test and can pick up a small amount of viral 
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particles. It is the test of choice for infants as it detects viral particles rather than the 
maternal antibodies that can circulate in an infant’s body up to the age of 15 months 
(Alexander, 2016; WHO, 2007; Fearon, 2005). PCR testing is considered the gold 
standard of testing for HIV in infants (Mazanderani et al, 2015). 
 
PCR testing in South Africa was introduced in 2004 in infants from six weeks of age 
(Meyers et al, 2007). The test, done at six weeks, was done in conjunction with the 
scheduled vaccinations. Testing at six weeks was, however, too late to detect in 
utero and intrapartum HIV infections and did not support the PMTCT program. It did 
not detect HIV infections that caused infants to die before the age of six weeks, and 
was too early to detect HIV infections that were supressed by NVP (Nevirapine) or 
maternal prophylaxis that crossed the placenta or in breastmilk. The PCR test done 
at six weeks had decreased sensitivity due to the neonates increased duration of 
exposure to preventative drugs (Sherman, 2015).  
 
PCR testing is now done on HIV exposed infants at birth, and then follow-up testing 
is done at ten weeks of age as well as six weeks after stopping breastfeeding if the 
child is under 18 months (Sherman, 2015; Department of Health, South Africa, 2016). 
Lilian et al. (2013) demonstrated that 76% of all early HIV infections were detectable 
at birth, and because of this PCR testing at birth is an appropriate way of detecting 
infection early and initiating early ART. This will reduce the early morbidity and 
mortality of infants infected with HIV. 
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2.6 Central Nervous System Involvement in HIV  
2.6.1 Entry of HIV into the CNS 
The CNS is commonly affected by HIV and there is a diverse spectrum of 
presentations (Boisse et al, 2008). Children infected perinatally are especially at risk 
for CNS involvement (Belman, 1992).  
 
Invasion of the CNS (brain and cerebrospinal fluid) occurs early after infection when 
the virus crosses the blood brain barrier (Puthanakit et al, 2013; Nozyce et al, 2006; 
Blumberg et al, 1994; Sharer, 1992). A study has shown HIV infection present in the 
CNS as early as eight days after infection (Valcour et al, 2012). HIV infects CD4+ T 
lymphocytes and macrophages. It is these macrophages that are involved in the 
changes that damage the CNS (Zayyad & Spudich, 2015; Ellis et al, 2009; An et al, 
1999; Blumberg et al, 1994; Johnson, 1993).  
 
There are two pathways that cause neuronal damage in HIV. Large numbers of 
astrocytes are actively or latently infected with HIV-1. This leads to neuronal 
dysfunction through loss of supporting growth factors, excitotoxicity due to 
dysregulation of neurotransmitter reuptake and loosening of the blood-brain barrier, 
which allows further infection of the CNS with HIV-1. In addition, macrophages 
infected with HIV-1 begin an inflammatory process. Macrophages and astrocytes 
interact, producing neurotoxic cytokines, viral proteins and nitric oxide. These two 
factors combined can result in widespread tissue disease and severe neurological 
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impairments (Gannon et al, 2011; Boisse et al, 2008; Blumberg et al, 1994; 
Gendelman et al, 1994).  
 
2.6.2 CNS changes and HIV Encephalopathy 
The most common clinical feature of HIV-related CNS disease is HIVE. HIVE is 
defined as the disease, damage or malfunction of the brain caused by HIV-1 (Donald 
et al, 2015). It is the failure to achieve, or the loss of previously achieved cognitive 
and motor milestones (Hilburn et al, 2010). HIVE is an AIDS-defining illness (Patel et 
al, 2009).  
 
As HIV invades the central nervous system, there is an increased risk of brain 
damage. This presents as intracerebral calcifications and microcephaly, as well as 
global neurodevelopmental delay (Walker et al, 2013; Hilburn et al, 2010).  
HIV affects the motor centres of the brain early on in the infection, causing tremor, 
ataxia and spasticity (Boisse et al, 2008; Boivin et al, 1995).  HIV can cause damage 
to the CNS in two ways: disease can be primarily caused by HIV (HIVE) and 
secondarily there can be CNS disease caused by opportunistic infections (such as 
meningitis) (Ellis et al, 2009). The use of ART decreased the number of opportunistic 
diseases of the CNS, and the most commonly seen dysfunction in the CNS has 
changed to primary HIV disease (Ellis et al, 2009; Boisse et al, 2008; Langford et al, 
2003). 
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Infiltration of CNS by HIV occurs at a very early age, and the initial infiltration causes 
subtle changes in the structure of the white matter (Donald et al, 2015; Mann et al, 
2015). The severity of the condition depends on the age of the child when infected. 
Children that experienced perinatal infection have more severe signs when 
compared to those infected postnatally. The developing brain is severely impacted by 
HIV, these infants experience more severe infections than adults (Donald et al, 
2015). It is thought that HIV infection reduces the growth of brain cells in-utero (Mann 
et al, 2015; Tardieu et al, 2000). When HIV-1 encephalopathy is present there is 
myelin pallor, reactive astrogliosis, reduced neuronal density and changes to the 
neocortical dendritic processes (Blumberg et al, 1994; Gendelman et al, 1994; Wiley 
et al, 1991). 
 
The most common symptom of HIVE is motor disturbances (Ojukwa & Epstein, 
1998). This is first picked up as gross motor disturbance or delay in infants (Hilburn et 
al, 2011; Shead et al, 2010; Potterton et al, 2009). Some of these children then 
develop hypertonia in the lower limbs (Mann et al, 2015). HIVE can either be static 
(unchanging) or progressive (Donald et al, 2015). Progressive HIV-1 encephalopathy 
(PHE) presents with microcephaly, delay or regression of developmental milestones 
as well as pyramidal deficits (Belman et al, 1988). It was found in a study done in 
Cape Town, South Africa, that as many as 63% of the children with HIVE presented 
with spastic diplegia or long tract signs (Donald et al, 2015).  
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2.7 Paediatric HIV and Neurodevelopment 
Neurodevelopment in children with HIV can be impacted by numerous factors. These 
include the impact of the virus itself, ART regiment as well as environmental factors 
(Sherr et al, 2014). Sherr et al. (2014) found in a systematic review that 81% of 
studies done on children with HIV, found that they presented with some form of 
neurodevelopmental delay when compared with control groups. 
 
Neurodevelopmental delay is common in infants infected with HIV (Donald et al, 
2014; Abubakar et al, 2008) and occurs early in the infection due to the early 
invasion of the CNS by the virus (Puthanakit et al, 2013). The motor centres are 
affected (Boisse et al, 2008; Boivin et al, 1995). Many studies have found that a high 
percentage of infants with HIV exhibit global neurodevelopmental delay before their 
first birthday. All developmental domains have been shown to be affected, these 
include gross motor, cognitive and language delay (Hutchings & Potterton, 2013; 
Whitehead et al, 2013; Strehlau, 2013; Potterton et al, 2009; Sherr et al, 2009; 
Abubakar et al, 2008; Ballieu & Potterton, 2008; Van Rie et al, 2007). As described 
earlier in this review, HIV invades the CNS which causes structural changes to the 
brain which alters neurodevelopment (Donald et al, 2015; Tardieu et al, 2000; 
Gendelman et al, 1994; Blumberg et al, 1994; Wiley et al, 1991). 
 
2.7.1 Motor delay 
Motor delay includes both fine and gross motor delay. It is the most commonly 
measured developmental domain in HIV, and this is the area that is most consistently 
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found to be delayed (Laughton et al, 2012; Hilburn et al, 2011; Shead et al, 2010; 
Potterton et al, 2009; Van Rie et al, 2009; Abubakar et al, 2008; McGrath et al, 
2006). It has also been found that the percentage of infants found to have 
neurodevelopmental delay increases as they age (Whitehead et al, 2014; Abubakar 
et al, 2008). Ferguson and Jelsma (2009) found that two-thirds of children infected 
with HIV displayed a significant gross motor delay. This was compared to a 5.7% 
delay in a healthy age matched sample. 
 
Whitehead et al. (2014) found that infants as young as four months demonstrated 
varying degrees of developmental delay. Numerous studies have shown that there is 
gross motor impairment (McGrath et al, 2006; Boivin et al, 1995; Msellati et al, 1993). 
It has also been noted that motor delay is seen early in the disease (Boivin et al, 
1995). This changes from a moderate impairment at six months to a severe 
impairment at eighteen months (Abubakar et al, 2008).   
 
Abubakar et al. (2008) concluded that motor development was the most frequently 
measured area and provided consistent evidence of delay in children infected with 
HIV.  
 
Gross motor delay is caused by changes in the CNS, caused by the virus (Donald et 
al, 2015). There is also loss of body protein, as well as abnormal metabolism of 
protein during HIV infection (Hsu et al, 2005). Abnormal protein metabolism can 
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cause reduced muscle leading to weakness and it has been suggested that gross 
motor delay could also be as a result of decreased muscle strength (Baillieu & 
Potterton, 2008). A recent South African study found that functional participants 
infected with HIV, were weaker than their uninfected peers, this suggests a link 
between HIV and muscle weakness (Naik & Potterton, 2017).  
 
 2.7.2 Cognitive delay 
There were discrepancies between the degrees of cognitive impairment reported in 
children infected with HIV. Bagenda et al. (2006) reported no significant difference in 
the performance of HIV infected children and the controls, whereas Boivin et al. 
(1995) reported severe levels of impairment, but only between the ages of three to 
six years. In younger children (three months to eighteen months) it was found that 
social development was impacted in children with HIV (Boivin et al, 1995). A South 
African study showed a significant delay in the cognitive development of HIV positive 
infants (Baillieu & Potterton, 2008). 
 
A recent South African study used the Griffiths Scale of Mental Development (GSMD) 
to ascertain the developmental status of preschool children receiving cART. It 
showed that the children were delayed in all facets of development except person-
social development. It showed that at preschool age the most affected facet of 
development related to cognition and perceptual abilities. This relates to poor 
performance at school (Potterton et al, 2016). 
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The reasons for cognitive delay have not been well explored. A 2017 study used MRI 
imaging to investigate the structure of the brain in paediatric patients with HIV. This 
study found altered cortical and subcortical structures in the study participants when 
compared to healthy controls. The participants also had significantly lower cognitive 
performance (Yadav et al, 2017). This suggests that the cognitive delay is, at least in 
part, due to structural changes in the brain. 
  
2.7.3 Language delay 
There are different findings in the extent of language delay in HIV infection. Msellati 
et al. (1993) and Boivin et al. (1995) reported no significant delay in language scores 
achieved in infants between six to eighteen months, but by 24 months Msellati et al. 
(1993) reported severe impairment. A 2008 study reported 77% delay in language 
comprehension and 85% delay in language expression in children with HIV between 
the ages of 18 months to 72 months (Van Rie et al, 2008).  Le Doaré (2012) reported 
subtle delays in language scores of older children with HIV who were receiving ART; 
while Baillieu and Potterton (2008) studied children with HIV from 18 months to 30 
months. This study reported language delay in 82.5% of the study participants 
(Beillieu & Potterton, 2008). 
 
Potterton et al. (2016) reported significant delay in the GSMD hearing/speech scores 
of preschool children receiving cART. These children showed a twelve month delay 
when compared with the normed population (Potterton et al, 2016).  
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Language delay can be related to motor difficulties due to difficulties with co-
ordination and control of oral muscles. It can also be attributed to cognitive delays 
causing delayed language development (Baillieu & Potterton, 2008; Wolters et al, 
1995).  
 
2.7.4 Gross motor delay as an early identifier of global delay 
Gross motor delay is not only noted in infants infected with HIV. It has also been 
suggested that motor delays may be the first (or most easily identified) indication of a 
global developmental delay. As infants develop it is expected that they acquire a 
variety of motor skills early on. Those at risk for global delay may struggle to reach 
early motor milestones (Noritz et al, 2013). Numerous studies have identified gross 
motor skills as the area most commonly impacted by HIV infection (Laughton et al, 
2012; Hilburn et al, 2011; Potterton et al, 2009; Shead et al, 2010; Van Rie et al, 
2009; Abubakar et al, 2008; McGrath et al, 2006). 
 
In addition, gross motor delay has been found as early as four months (Whitehead et 
al, 2014; Abubakar et al, 2008; Boivin et al, 1995). In order to assess an infant and 
pick up delay early on, a tool that can identify gross motor delay early would be most 
appropriate. 
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2.8 Impact of Timing of HIV Infection on Neurodevelopment  
McGrath et al. (2006) investigated children infected with HIV before 21 days old. 
They scored significantly lower on the cognitive scales than those infected after 21 
days. There was a small delay at the age of six months, and by eighteen months a 
larger delay. Infants who present with the most severe neurodevelopmental delay are 
those that are diagnosed before the age of three months, and were exposed to the 
disease very early (Le Doaré et al, 2012), therefore, the earlier the infant is infected, 
the more severe the extent of neurodevelopmental delay. 
 
A study done on the neurodevelopment of infants with early and late HIV infections 
was done by Smith et al. (2000). Early infected infants received a positive diagnosis 
within the first 48 hours of life, whereas the late infected group were diagnosed after 
48 hours. The Bayley Scales of Infant Development (1st Version) was used to assess 
the infants in this study. It was found that infants infected early had significantly lower 
scores on the mental and motor scales by the age of 24 months (Smith et al, 2000).  
 
2.9 Impact of ART on Neurodevelopment 
The early introduction of ART has been found to improve neurodevelopmental 
outcomes and reduce the incidence of HIVE (Whitehead et al, 2014; Puthanakit et al, 
2013; Strehlau, 2013; Natchman et al, 2012; Thomaidis et al, 2010; Chiriboga et al, 
2005; Epstein et al, 1986). South Africa has implemented the early introduction of 
ART for infants with HIV, which will combat the infection early, reducing the extent of 
CNS damage (Lilian, 2013).  It has been observed that ART medications must be 
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able to cross the blood-brain-barrier in order to combat the infection in the brain 
(Letendre et al, 2008). A 2009 study showed a 50% reduction in HIVE when ART 
included medication that could cross the blood-brain-barrier when compared to 
patients receiving regimes that did not (Patel et al, 2009). After commencement of 
ART, the sequelae of HIVE may improve, but the damage that was done prior to 
initiation persists (Langerak et al, 2014; Walker et al, 2013). 
 
The Children with Early Antiretroviral Therapy (CHER) trial, was a randomised control 
trial in asymptomatic HIV positive infants younger than 12 weeks in South Africa. It 
included a group that received immediate ART for 40 weeks or received immediate 
ART for 96 weeks; these infants received ART at the time of diagnosis. The deferred 
ART group received ART when their CD4% was less than 25% in infancy, or CD4% 
less than 20%, or Centres for Disease Control and Prevention severe stage B or 
stage C disease. The trial found that the group that received deferred ART had a 
higher incidence of HIVE when compared to the groups that received early ART. It 
has been suggested that early ART could be neuroprotective (Cotton et al, 2013; 
Puthanakit et al, 2013).  
 
In a cross-sectional sub-study of the CHER trial, Laughton et al. (2012), described 
the neurodevelopmental outcomes in infants receiving deferred ART compared to 
early ART (as described in the previous paragraph). The infants receiving deferred 
ART scored lower on the GMDS then those receiving early ART. Those receiving 
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early ART had GMDS scores similar to those HIV-uninfected infants except in the 
locomotor subscale (Laughton et al, 2012).  
 
The PREDICT trial concluded that the ideal time for initiation of ART was in early 
infancy (Puthanakit et al, 2013). In a literature review Le Doaré et al. (2012) found 
that infants who received ART prior to 12 weeks of age had improved scores on 
standardised developmental tests. It was also noted that older children who were 
treated with ART had scores that were near to normal global developmental scores 
(Le Doaré et al, 2012). 
 
2.10 Developmental Screening 
It has been estimated that worldwide 200 million children under the age of five fail to 
meet their developmental potential (Grantham-McGregor et al, 2007). There has 
been an increasing emphasis on early identification of developmental disorders. By 
conducting developmental surveillance, screening and assessment where 
appropriate, developmental outcomes can be improved (Engle et al, 2011; Council 
on Children with Disabilities, 2006; Blackman, 2002). 
A certain set of skills is expected to be attained in infancy and early childhood. There 
are multiple factors that can have a negative impact on a child’s development. These 
include poverty, malnutrition, recurrent or chronic infections as well as inadequate 
cognitive stimulation (Sabanathan et al, 2015; Engle et al, 2011). In developing 
countries children are at a greater risk of these factors influencing their development, 
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and adequate identification and intervention in these cases is vital. When an 
individual fails to attain these expected domains, developmental delay is diagnosed 
(Al Notal & Schwenk, 2013). 
In order to accurately assess developmental domains, standardized tools should be 
used. Numerous screening tools have been developed worldwide. Western 
screening tools are often inappropriate for the developing world. Western tools can 
either be adapted to make them appropriate for use, or new tools can be created to 
suit a specific population (Kammerer et al, 2013).   
 
Screening is a “brief assessment procedure designed to identify children who should 
receive more intensive diagnosis or assessment” (Meisels, 1988 pg 527). Screening 
tools need to be administered quickly and have a limited sample of items that 
represent a domain and have a definite cut-off point. They are used to identify infants 
and children that may have neurodevelopmental delay, and further in-depth 
assessment should be done to determine the exact nature and extent of the delay. 
Screening tools can miss subtle neurodevelopmental delays which can impact on 
development later in life. They are found to be especially useful as part of a 
developmental surveillance program where infants and children can be monitored 
over time (Sabanathan et al, 2015).  
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2.10.1 Methods of assessment 
The methods employed by various screening tools include: 
1. Direct assessment. Standardised activities are done with a trained assessor 
in a clinical environment.  
2. Indirect assessment. This includes verbal reporting or completion of a 
questionnaire by a parent, teacher or guardian as well as structured 
observations.  
3. Unstructured observations. A trained assessor observes a child in a familiar 
environment.  
Tools can use one or a combination of the above methods in order to assess a child 
(Sabanathan et al, 2015; Kammerer et al, 2013). Developmental screening is often in 
the form of an indirect assessment and are advantageous, as they take a short 
period of time to administer (Kammerer et al, 2013). Sub-Saharan Africa has 
numerous constraints that prevent in-depth assessment of each at-risk individual. 
This makes a reliable screening tool vital in this setting. Once screened and identified 
as being at-risk, children can be referred for further assessment and, if needed, 
therapeutic intervention.  
2.10.2 Developmental domains 
There are numerous developmental domains that can be assessed by a screening 
tool, namely: cognitive, language (expressive and receptive), motor (fine and gross), 
socio-emotional and adaptive behaviour (Sabanathan et al, 2015; Kammerer et al, 
2013).  
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A tool can either focus on one, or include numerous domains. For example the 
IGMST is a screening tool that screens for gross motor delay in infants that are  
infected with HIV (Hilburn et al, 2011) whereas, the Bayley Infant 
Neurodevelopmental Screener (BINS) includes four different developmental areas 
(basic neurological functions, expressive functions, receptive functions and cognitive 
functions) (Aylward & Verhulst, 2000). Historically, tests of global neurodevelopment 
have been employed in the African setting, as more tests are created and adapted, 
single domain tests are being used (Kammerer et al, 2013). 
 
2.11 Development of a Screening Tool  
2.11.1 Content validity 
A screening tool should undergo testing before it is used. Initially its content validity 
should be examined. According to Lynn, 1985; validity “is the extent to which that 
instrument measures what it is intended to measure’’ (Lynn, 1986, pg 382). Validity 
includes content, criterion and construct validity. Content validity should be looked at 
as a two-stage process, namely development and judgement. The developmental 
phase should include domain identification (identifying which domain is being 
assessed), item generation (which items should be included) and instrument 
formation (placing items together in a usable form). These steps can vary slightly 
depending on the context in which they are being used (Lynn, 1986). 
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Following this, the tool must undergo judgement. This can be by a predetermined 
group of experts. This should be done for each individual item as well as for the 
instrument as a whole. These experts should achieve agreement for content validity 
to be established. (Lynn, 1986).The Nominal Group Technique (NGT) and the Delphi 
survey are the most commonly used formal methods for determining consensus 
agreement (Harvey & Holmes, 2012). 
 
2.11.2 Nominal group technique  
The Nominal Group Technique (NGT) is a structured, face to face meeting to 
determine content validity. It is a tool to generate information and determine 
consensus agreement.  It follows a set process, and on completion of the meeting, 
members of the panel have reached consensus (Harvey & Holmes, 2012).  
 
Between five to nine experts should be included in the discussion. A consensus of 
80% should be reached (Potter et al, 2004). Experts should be invited to participate 
in the panel discussion and the following steps should be followed: 
1) Introduction and explanation: The meeting should begin with introduction and 
an explanation and the participants given the purpose and procedure of the 
meeting. 
2) Silent Idea Generation: The participants are provided with a sheet of paper 
and asked to write down all the ideas that came to mind when thinking about 
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the questions presented during the discussion. During this time the 
participants are asked not to speak or share ideas. 
3) Idea Sharing: Participants are invited to share their ideas. Each participant is 
given time to present their ideas. Any new ideas generated by any participants 
are written down. This allows all participants to contribute equally and provides 
a written record. There is no debate or discussion at this point in the meeting.  
4) Group discussion and clarifying: Participants are asked to comment, or ask 
their colleagues for further detail on any of the ideas produced. 
5) Voting and ranking: The ideas are then prioritised in relation to the original 
question asked. Results are immediately available to the participants. When 
the meeting is concluded the results were available to the participants. 
(Harvey & Holmes, 2012).  
 
A nominal group technique was used to successfully establish the content validity of 
the Gross Motor Function Classification System (GMFCS) (Palisano et al, 1997) as 
well as the expanded and revised version of the same tool (Palisano et al, 2008). It 
was also used successfully during the development of the original IGMST (Hilburn et 
al, 2011). 
 
2.11.3 Requirements of a screening tool in a resource poor area 
In a developing country a screening tool should meet certain criteria. It should identify 
those children who are experiencing developmental problems in order for them to be 
referred for additional assessment. The tool should be sensitive enough to 
28 
  
distinguish between children who have developmental delay and those who do not. 
Time constraints should be considered. It should be quick and easy to administer, 
both to reduce the time taken for the assessor to get through a large volume of 
patients, but also to reduce the assessment time for a young child. Specific training 
on administration of the tool should not be required. Nurses or counsellors could 
administer it, if need be. Budget should be taken into consideration. The tool should 
be inexpensive and should not require any specialised equipment or forms 
(Kammerer et al, 2013; Hilburn et al, 2011). 
 
2.12. Infant Gross Motor Screening Test 
2.12.1 Purpose and administration 
The Infant Gross Motor Screening Test (IGMST) (Appendix IV) was developed to 
screen for gross motor delay in infants infected with HIV.  It is a valid and reliable tool 
that can be used to screen for gross motor delay in infants from six to eighteen 
months. The IGMST requires no specific training to administer. It was created after it 
was found that the Bayley Infant Neurodevelopmental Screener (BINS) was an 
inappropriate tool for South African HIV infected infants (Hilburn et al, 2011). 
 
2.12.2 IGMST development 
The IGMST was developed by selecting six gross motor items per age group from 
the Bayley Scales of Infant Development (3rd version) (BSID III) which distinguished 
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an infant scoring in the At-Risk, Emerging or Competent categories. These items 
were then statistically tested using a Kappa statistic to assess agreement. The items 
selection was adjusted and refined until excellent agreeability was achieved in 
statistical testing (Hilburn et al, 2011). 
 
2.12.3 Statistical properties  
Content validity was carried out by a panel of experts in the field of paediatrics using 
a modified Nominal Group Technique (NGT), and agreement of 80% was required. 
Concurrent validity was carried out on 60 infants using the gross motor section of the 
BSID III, and excellent agreement was found (Kappa 0.85). Preliminary statistical 
testing showed it to have high sensitivity (97.4%) and specificity (85.7%). It also has 
a high positive predictive value (PPV) of 92.7% and negative predictive value (NPD) 
of 94.7%.  Reliability testing was carried out using 30 infants and found excellent 
inter-rater, test-retest and intra-rater reliability. The diagnostic properties were found 
to be excellent and preliminary testing showed it to be a valid and reliable tool to 
screen for gross motor delay in infants infected with HIV (Hilburn et al, 2011).  
 
2.12.4 The need for expansion of the original IGMST 
The number of assessment tools for young children and infants is very limited when 
compared to the number available for school-going children. Thus, tools that can be 
used on this population are needed (Kammerer et al, 2013). In order to appropriately 
plan for interventions for children with HIV, developmental milestones must be 
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understood in this group (Le Doaré et al, 2012). At the time of Hilburn et al’s. 2011; 
study PCR testing was carried out at 6 weeks, and infants were not always identified 
early enough to prevent morbidity and mortality (Lilian et al, 2013). Infants are now 
identified as HIV positive at an earlier age due to PCR testing at birth. Early 
identification of this high-risk population means that developmental surveillance, and 
where required, therapeutic intervention, can begin earlier. 
 
McGrath et al. (2006) suggested that as there is an increased survival of children 
receiving ART, it is important to set up services that promote the neurodevelopment 
of these children. It was also suggested in another unpublished study, that early 
identification and referral needs to be done in order to improve the 
neurodevelopmental outcomes of children with HIV (Strehlau, 2013). 
 
2.13 Other Locally Developed Screening Tools 
2.13.1 Red Cross War Memorial Screening Tool (RCWMST) 
The Red Cross War Memorial Screening Tool (RCWMST) was developed in 2014 to 
screen for neurodevelopmental delay in children infected with HIV in South Africa. It 
can be used on children from nine to thirty-six months with moderate to severe 
developmental delay. The nine and eighteen months items were adapted from the 
Western Cape Developmental Screening Tool and the twenty-four and thirty-six  
month items were selected from the Denver Developmental Tool, the Molteno 
Adapted Scales and clinical experience (Boyede et al, 2015). 
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The age categories were selected to coincide with the vaccination schedule, and can 
only be used at these points time. It is a multi-domain screening tool and tests for 
delay in motor (gross and fine), communication and social behaviours. It also 
includes a list of warning signs for each age, as well as the action to be taken should 
the test be failed.  It consists of six sections with tick boxes for each item. It requires 
a short time to administer and no specific equipment which makes it useful in the 
South African clinic setting (Boyede et al, 2015). 
 
Concurrent validity was carried out against the BSID III and it was found that the tool 
has a sensitivity of 78.5%, which is acceptable. It has a specificity of 54.6%, which 
was deemed moderate, authors suggest this is due to the emphasis of the tool being 
on sensitivity. Its PPV is 42.3%, which is low, and NPV is 85.7% (Boyede et al, 
2015). The statistical properties of this tool indicate that there may be over referral, 
which can lead to too many assessments being done and leading to time being 
wasted.  
 
2.13.2 The Road to Health Booklet 
This locally developed tool is not specific to the HIV population. The Road to Health 
Booklet (RTHB) was introduced in October 2010 as part of the South African 
Department of Health’s plan to improve service delivery to infants and young 
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children. It should be distributed to all infants in the private and state sectors. It 
contains a developmental screener that consists of three questions that should be 
asked at each visit and specific questions for each age group. It aims to screen for 
delays in vision and adaptive behaviour, hearing and communication and motor 
development (South African Department of Health, 2017). 
 
Van der Linde et al. (2015) conducted a study to compare the RTHB with Parents’ 
Evaluation of Developmental Status (PEDS). It was found to have poor correlation 
with the PEDS. Sensitivity was found to be 25% and specificity 91%. It was found to 
be ineffective at identifying delay, and should be adapted or replaced to ensure 
adequate identification of infants with neurodevelopmental delay (Van der Linde et al, 
2015). 
 
In an unpublished dissertation, the use of the RTHB screening test was investigated. 
It compared the use of the screening section in the RTHB, to parental report and 
paediatrician assessment. This study found that primary care nurses using the tool 
reported 13% delay, compared to parent report which indicated 25% of the 
population presenting with delay. In this case the examining paediatrician found 28% 
delay. It was concluded that the RTHB screening test is not used optimally in the 
primary care setting to detect developmental delay (Naborn, 2016). 
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2.14 Early Intervention 
Early intervention is based on the concept of brain plasticity. Plasticity involves the 
brain’s ability to form new synaptic connections and remove excessive ones. This 
allows the brain to change and learn from new experiences (Sullivan et al, 2014; 
Johnston et al, 2000). In order to allow early intervention to take place, the infants at 
risk of delay need to be identified as soon as possible. With the improved prevention 
and treatment of HIV in sub-Saharan Africa there must be adequate screening, 
neurodevelopmental assessment and identification of those in need of intervention. 
(Whitehead et al, 2014; Kammerer et al, 2013; Potterton et al, 2011; Hilburn, 2010; 
Grantham-McGregor et al, 2007). 
 
A systematic review on early intervention on motor development, concluded that 
early intervention, using general developmental programs, is effective in improving 
the motor outcomes in full term high-risk infants (Blauw-Hospers & Hadders-Algra, 
2005). Other studies have also shown that early intervention and stimulation 
programs can improve the presentation of neurodevelopmental delay (Potterton et al, 
2010;  Blackman, 2002). The goal of early therapeutic intervention should be to 
address existing developmental issues as well as minimising any further physical, 
cognitive and emotional delay.  
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2.15 Conclusion 
In order to improve the developmental outcomes and quality of life of infants infected 
by HIV, it is vital to offer them the intervention and support that they need. Infants 
with HIV need additional care to allow them to thrive. By identifying those requiring 
assessment and physiotherapy intervention as early as possible, it will offer them the 
best chance of giving them the support they need.  
 
There is no developmental screening tool available to screen for gross motor delay in 
infants under the age of six months, which has been developed and validated for this 
population.  
 
 
 
 
 
 
 
 
 
 
35 
  
CHAPTER 3 
3 PHASE ONE – SCREENING TOOL DEVELOPMENT- METHODOLOGY & 
RESULTS 
3.1 Development of a New Section of the IGMST 
This study was based on the study which developed the initial IGMST by Dr Nicole 
Hilburn titled ‘’ The development of a screening tool to evaluate gross motor function 
in HIV-infected infants’’ (Hilburn et al, 2011). In order to create an addition to the 
exisiting screening tool, the original methods were replicated.  
 
This chapter will present the first phase in the development of the new section of the 
IGMST. 
 
3.2 Objectives  
The objectives of phase one were as follows: 
• To identify gross motor items from the BSID III which would be suitable for 
inclusion in the IGMST to extend it for use in younger infants (one to five 
months). 
 
• To categorise items into age group suitability (one to three months); (four to 
five months). 
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• Testing and refinement of the initial version of the new items to satisfy 
statistical criteria (Pearson’s correlation ≥0.7). 
 
3.3 Ethical Considerations 
Ethical clearance was obtained from the Human Research Ethics Committee 
(Medical) of the University of the Witwatersrand prior to starting the data collection 
process (clearance certificate number M160503, see appendix II). 
 
Permission was obtained from the author of the IGMST (see appendix IV) to extend 
the screening tool (see appendix III). Permission was also obtained from the holder 
of the data sets to access the data and extract the relevant information (see appendix 
V). 
 
3.4 Study Design 
Phase one of the study was a retrospective record analysis. 
 
3.5 Study Population 
Two 2013 physiotherapy masters studies, completed through the University of the 
Witwatersrand, investigated the neurodevelopment of infants infected with HIV using 
the BSID III. The completed BSID III from Whitehead et al. (2014) study titled “The 
neurodevelopment of HIV-infected infants on HAART compared to HIV-exposed but 
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uninfected infants” (Ethical clearance certificate M10535) and Hutchings et al. (2013) 
study titled ‘’Developmental delay in HIV-exposed infants in Harare, Zimbabwe” 
(Ethical clearance certificate M110484) were analysed in this study. BSID III 
assessments meeting the inclusion criteria below were selected for analysis. 
 
3.6 Sample Size 
The sample size was based on an expected success proportion of 0.8 with 
significance set at 0.05 (Hilburn et al, 2011). In order to have a Pearson’s Correlation 
of 0.70, a sample of at least thirteen infants per age band is required. A sample of 
twenty five (n=25) infants for age band one to three months and eighteen (n=18) for 
age band four to five months was used. In total forty three (n=43) infants were used 
in this study. 
 
3.7 Inclusion Criteria 
BSID III forms of infants confirmed HIV positive from birth to five months from the 
available data sets. 
 
3.8 Exclusion Criteria 
BSID III with any missing data were excluded. 
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3.9 Measurement Tools – BSID III 
The Bayley Scales of Infant Development III (BSID III) is an instrument which 
assesses developmental functioning of infants and young children aged between one 
and forty-two months which is administered on an individual basis. The BSID III is 
reliable and valid, and is predictive of later developmental outcome (Bayley, 2006). 
The BSID III has been considered the ‘gold standard’ in infant developmental 
assessment, which is why it was chosen (Harris et al, 2005). Studies have been 
conducted using the BSID III on typical black African infants (zero to eighteen 
months) in Johannesburg, who have socioeconomic backgrounds similar to the study 
population. Results of this study showed the infants did well to above average in the 
BSID III. This makes it a suitable tool to base the new section of the screening tool 
(Rademeyer, 2010; Brown, 2009).  
 
3.10 Procedure 
The procedure is as out-lined in the Figure 3.1 below: 
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Figure 3.1 Process of development for the new section of the IGMST 
 
3.10.1 Analysis of gross motor items by age group 
Completed BSID III were sorted and those fulfilling the inclusion and exclusion 
criteria were selected for further analysis. The analysis determined which gross motor 
items from the original BSID III should be included in the IGMST. The item analysis 
was performed by entering scores into an Excel spreadsheet. 
 
Each item received a score; namely: 
1=credit 
0=no credit 
2= finish the test (i.e. after obtaining five zero’s in a row)  
 
Development of the new section of the IGMST
Analysis of gross motor items by age group
First version of the new section of the IGMST developed and scoring determined
First version was tested against the study data using the Pearson's correlation coefficient
Agreement was found to be sufficient
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The data were then entered according to age group and grouped according to the 
score obtained on the BSID-III; namely: ‘At-Risk’, ‘Emerging’, and ‘Competent’ (See 
appendix VI for example).  
 
Percentages of the number of infants that completed an item were then obtained.  
Items were selected for each age group according to the percentages obtained.  
 
The items selected for the new section of the IGMST were those that discriminate 
between the ‘At-Risk’ and ‘Emerging’ and ‘Competent’ groups. Five items were 
selected for each age band (one to three months and four to five months). The first 
two items should be achieved by the majority of the infants (≥70%, or as close to 
100% as possible), the second two items done by some of the infants (30% - 69%) 
and the final item by few of the infants (≤29%). This selection ensured that the most 
advanced infants were able to do all the selected items, while those experiencing 
neurodevelopmental delay scored as ‘At Risk’ and were identified for further 
assessment. Table 3.1 illustrates the selection. 
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Table 3.1 Item selection 
Item  Percentage of Infants able to complete item 
One ≥70%, 
Two ≥70%, 
Three 30% - 69% 
Four 30% - 69% 
Five  ≤29% 
 
The items selected needed to fulfil the following criteria, namely: 
1) The items needed to be observational (the infant should require minimal handling). 
2) The items must reflect a movement rather than the quality of movement. 
 
Selection of items was done in conjunction with a literature search to determine 
which items would be most indicative of delay (Bly, 2011; Bayley, 2006; Harris & 
Daniels,1996; Aylward, 1995; Piper, et al., 1992). During the item selection there 
were two versions of the four to five age band developed. Version one included items 
which the literature deemed more appropriate and indicated early abdominal 
activation, while version II was the best fit and would most likely perform well 
statistically. 
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The items that were selected were grouped according to age bands (one to three 
months and four to five months). Scoring was determined according to the following: 
the oldest infants should be able to obtain credit for most/all items to be competent. 
The younger infants should have been able to obtain one less credit to be considered 
competent. The selection and scoring was done in conjunction with a literature 
search to determine which items were appropriate for each age band (Bly, 2011; 
Bayley, 2006; Harris & Daniels,1996; Aylward, 1995; Piper, et al., 1992). Table 3.2 
illustrates the scoring for one to three months age band. 
Table 3.2 Scoring 
Age Score to be obtained to be placed 
in the Satisfactory category 
Score to be placed in the At-
Risk category 
1 months 1-5 0 
2 months 3-5 0-2 
3 months 4-5 0-3  
 
The first draft of the new items for the screening tool was statistically tested against 
the initial BSID III data to determine the agreeability of the new test and the BSID III. 
Correlations between the new items and the items on the BSID III were carried out 
using the Pearson’s correlation. Results were then analysed.  
 
3.10.2 Testing of the first version of the new items for the IGMST 
After the items had been selected and scoring assigned, the new section of the 
IGMST was ready for testing against the original BSID III data. The comparison was 
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using only the gross motor scale. The comparison was with the scaled scores on the 
BSID III. Forty three BSID III assessments where compared to the new section of the 
screening tool in the selected age groups. The age groups and number of infants is 
outlined below in Table 3.3 
 
Table 3.3 Age groups for testing according to the new items of the IGMST (n = 43) 
Age Number 
1-3 months 25 
4-5 months 18 
 
3.10.2.1 Statistical analysis 
The data were entered into an Excel spreadsheet, and the statistical analysis done in 
consultation with a statistician from the National Institute for Occupational Health.  
Correlations between the new items and the items on the BSID III were carried out 
using the Pearson’s correlation coefficient (using STATA Version 14.2) Pearson ≥ 
0.70 indicates good agreement. The results are presented in Table 3.4 below: 
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Table 3.4 Agreement between the BSID III and the new section of the IGMST (n=45) 
Age Group Pearson’s correlation(r) P Value Percentage of Children 
whose Scores 
Correlated on both 
Tools 
1-3 months 0.68 0.003 84% 
4-5 months (Version I) 0.71 0.0009 83% 
4-5 months (Version II) 0.76 0.0002 88% 
  
Agreement was good in both tested versions of the four to five month group where 
Pearson’s correlation ≥ 0.7 indicates good agreement. The data for the one to three 
month group were found to have a modest correlation, but at 0.68 were very close to 
good correlation of 0.7 (Jogi et al, 2011). 
 
3.10.2.2 Analysis of results 
The data for the one to three month age group were analysed to determine if these 
scores could be improved. It was decided that other possible combinations would 
only weaken the statistical performance of the test and the final decision of the items 
would be left to the expert panel to make. The new section of the screening tool was 
then ready to be presented to an expert panel in the field of paediatrics. Figure 3.2 
illustrates the first version of the items for the new section of the IGMST. 
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1 – 3 months  
1. Turns head to sides (object of interest): Child turns head from one side to the other by 
raising his or her head off the supporting surface enough to clear the nose. Child must be 
able to turn to both sides. 
2. Attempts to bring hand to mouth: Child purposely attempts to place his or her hand in 
mouth. 
3. Controls head while prone: 45° (object of interest): Child maintains raised head at least 45° 
from exam surface for at least 2 seconds.  
4. Controls head while upright (15 seconds): Child holds head erect and steady for at least 15 
seconds 
5. Rolls from side to back: Child actively from both sides to his or her back. 
 
 
Scoring:  
1 month:    0 At Risk 
      1-5 Satisfactory 
2 months:   0-2 At Risk 
       3-5 Satisfactory 
3 months:   0-3 At Risk 
       4-5 Satisfactory 
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4-5 months (I) 
1. Holds head in midline (object of interest): Child holds head in midline for at least 5 
seconds. 
2. Controls head while prone: 45° (object of interest): Child maintains raised head at least 45° 
from exam surface for at least 2 seconds. 
3. Sits with support: 30 seconds: Child sits with slight support for 30 seconds. 
4. Rolls from back to sides (object of interest): Child turns from back to both right and left 
sides. 
5. Grasps foot with hands: Child brings one or both feet up to hands (above the hips) and 
grasps a foot. 
 
 
Scoring: 
4 months:  0-2 At Risk 
      3-5 Satisfactory 
5 months:  0-3 At Risk 
      4-5 Satisfactory 
 
 
 
 
 
 
 
 
 
 
47 
  
4-5 months (II)  
1. Holds head in midline (object of interest): Child holds head in midline for at least 5 
seconds. 
2. Controls head while prone: 45° (object of interest): Child maintains raised head at least 45° 
from exam surface for at least 2 seconds. 
3. Rolls from side to back: Child actively from both sides to his or her back. 
4. Sits with support: 30 seconds: Child sits with slight support for 30 seconds. 
5. Rolls from back to sides (object of interest): Child turns from back to both right and left 
sides. 
Scoring: 
4 months:   0-2 At Risk 
       3-5 Satisfactory 
5 months:   0-4 At Risk 
      5 Satisfactory 
 
Figure 3.2 First version of the Items for the new section of the IGMST 
 
The first phase of the study was completed and the test was ready for scrutiny by an 
expert panel. A modified nominal group technique was chosen to complete content 
validity. Phase two of this study will be presented in Chapter Four. 
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CHAPTER 4  
4 PHASE TWO – CONTENT VALIDITY – METHODOLOGY & RESULTS 
4.1 Content Validity of the New Section of the IGMST 
This chapter will present phase two of the study. A NGT was chosen to examine the 
content validity of the new section of the IGMST.  
 
4.2 Objectives 
The objectives for phase two were as follows: 
• To complete preliminary content validity through an expert panel examining 
the tool and making adjustments accordingly.  
• To design and layout the new age bands in keeping with the format of the 
IGMST. 
 
4.3 Ethical Considerations 
Written invitations, including an information sheet, were sent to the expert panel to 
request their participation in the panel discussion (see appendix VII). 
 
4.4 Study Design 
Phase two made use of a panel meeting using a modified NGT (Potter et al, 2004). 
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4.5 Study Population 
An expert panel was invited to examine the content validity of the new section of the 
screening tool. Ten experts in the field of paediatrics were invited to attend the panel 
with the requirements being that between five and nine members attend the meeting. 
These experts included various disciplines with knowledge of early development. 
Written invitations (Appendix VII) were sent to each person describing the study and 
outlining the proposed meeting, as well as enquiring whether they would like to 
participate in the meeting. 
 
4.6 Inclusion Criteria 
• A minimum of five years of experience in the field of paediatrics 
• A medical, physiotherapy or occupational therapy degree 
• Currently practicing in the field of paediatrics 
• Preferably involved in research 
• Familiar with the administration of standardised assessment tools (Hilburn et 
al, 2011). 
 
4.7 Sample Size 
Potter et al. (2004) states that the five to nine experts should attend the meeting in 
order to fulfil the criteria for a modified NGT. Five experts attended the expert panel 
discussion. 
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4.8 Procedure 
A modified NGT (Potter et al, 2004) was followed to facilitate the panel discussion. 
The session was held in the physiotherapy department at the University of the 
Witwatersrand.  
 
The following steps were followed, as dictated by the NGT protocol: 
1) Introduction and explanation: The meeting began with an introduction and an 
explanation and the participants were welcomed. The participants were given 
an explanation of the purpose and procedure of the meeting. 
2) Idea Generation: The participants were provided with a sheet of paper and 
asked to write down all the ideas that came to mind when thinking about the 
questions presented. During this time the participants were asked not to speak 
or share ideas. 
3) Idea Sharing: After this the participants were then invited to share their ideas. 
Each participant was given time to present their ideas. Any new ideas 
generated by any participants during the idea sharing were written down. This 
allowed all participants to contribute equally and provided a written record. 
There was no debate or discussion at this point in the meeting.  
4) Group Discussion: Participants were asked to comment or ask their 
colleagues for further detail on any of the ideas produced. 
5) Voting and Ranking: The ideas were prioritised in relation to the original 
question asked. Results were immediately available to the participants. When 
the meeting was concluded the results were available to the participants.  
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The meeting was held with five experts in the field of paediatrics who fulfilled the 
inclusion criteria. The panel consisted of four physiotherapists and one medical 
doctor, all of whom were currently working in the field of paediatrics. All had more 
than 5 years’ experience, were involved in research and familiar with the 
administration of standardised assessments. 
 
On arrival the participants were provided with a copy of the original IGMST, new 
section of the screening tool and a copy of the proposal, which included the 
methodology used. They were asked to look through the documents provided to 
familiarise themselves with the tool. They were welcomed and introduced to one 
another. They were then given a verbal explanation of the development of the new 
section of the screening tool. An outline of the meeting and objectives for the session 
were given. Participants were asked to sign informed consent (Appendix VIII) after 
the introduction and explanation. 
 
The above protocol was followed, and the group was asked to comment on the 
following:   
1) Whether the age band two to three months could be expanded to one to 
three months without compromising the results of the tool. 
2) Whether the four to five (I) or four to five (II) was a more appropriate for the 
new section of the screening tool. 
3) Appropriateness of each selected item (the item itself, and item wording). 
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4) Appropriateness of the age groups which had been selected. 
5) Appropriateness of the items for the age-group in which they fell. 
6) Appropriateness of scoring. 
 
4.9 Statistical Analysis 
Consensus of 80% for each of the items discussed indicates agreement. Any issues 
arising during the discussion were addressed and adjustments to the screening tool 
were made when necessary.  
 
There was 100% consensus for items one, two, four, five and six. Item three had a 
consensus of 40%. Once discussion and appropriate changes were made, the 
agreement was 100%. Once all items received consensus of ≥80% the meeting was 
complete. Table 4.1 shows the agreement between participants for each question: 
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Table 4.1 Agreement between Participants for Each Question  
Question Agreement Agreement after suggested changes 
Whether the age band 2-3 months can be 
expanded to 1-3 months without 
compromising the results of the tool. 
100% n/a 
Whether the 4-5 (I) or 4-5(II) is a more 
appropriate tool. 
Option I 100% n/a 
Appropriateness of each item selected 
(the item itself, and item wording) 
40% 100% 
Appropriateness of the age groups which 
had been selected. 
100% n/a 
Appropriateness of the items for the age-
group in which they fell 
100% n/a 
Appropriateness of scoring. 
 
100% n/a 
The issues brought up at the panel discussion are outlined below: 
4.9.1 Issues brought up at the panel discussion 
It was raised at the discussion that the wording of the items was directly from the 
BSID III, and should be adjusted to original wording that is more easily understood, 
as well as to be more specific, regarding the starting position of each item. A starting 
position for each item was included in the description. 
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4.9.1.1 Age band one to three months 
Item one: ‘Attempts’ to bring hand to mouth was changed to ‘brings’ hand to mouth. It 
was specified that it could be either one or both hands. Item three: ‘raised head’ was 
changed to ‘lifts head’. Item five: Included ‘this should be voluntary, and initiate by 
turning the head’. 
4.9.1.2 Age band four to five months 
The literature indicated that acquiring abdominal control in supine is important for 
further development an important for further gross motor development (Bly, 2011). 
This can be demonstrated by the ability of an infant to lift their legs and grasp their 
feet. However from the sample in the study including this item would not produce the 
most statistically significant tool. For this reason two versions of the four to five age 
band were developed and scored. The decision as to which is more appropriate for 
the screening tool was left to the expert panel to make. 
 
• Item one was too easy for a four month old. It was suggested that the time be 
increased from five seconds to ten seconds.  
• Item two was too easy for the age group. The time was increased from two 
seconds to ten seconds. A description of the starting position of the shoulder 
was included, ‘the elbow must be in-line or in front of the shoulders’.  
• Item three needed clarity on ‘slight’ support. This was changed to ‘support by 
the hips on a flat surface’.  
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• Item five was too difficult. ‘Grasps’ foot was changed to ‘touches’ foot to 
make it easier. 
• In addition, the panel suggested that two items be added to the existing 
instructions for use of the IGMST. These were: 
o The child should be dressed in light clothing or nappy during 
administration. 
o A small toy can be used to attract the child’s attention if needed.  
  
 The revisions for both age bands are presented in figure 4.1 below: 
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FIRST VERSION 
1– 3 months  
1. Turns head to sides (object of 
interest): Child turns head from one 
side to the other by raising his or her 
head off the supporting surface 
enough to clear the nose. Child must 
be able to turn to both sides. 
2. Attempts to bring hand to mouth: 
Child purposely attempts to place his 
or her hand in mouth. 
3. Controls head while prone: 45° 
(object of interest): Child maintains 
raised head at least 45° from exam 
surface for at least 2 seconds.  
4. Controls head while upright (15 
seconds): Child holds head erect and 
steady for at least 15 seconds 
 
5. Rolls from side to back: Child 
actively from both sides to his or her 
back. 
 
Scoring:   1 month: 0 At Risk; 1-5 Satisfactory 
                2 months: 0-2 At Risk; 3-5 Satisfactory 
                3 months: 0-3 At Risk; 4-5 Satisfactory 
SECOND VERSION 
1-3 months 
1. Turns head to both sides while lying on 
stomach: Child lies on stomach, and turns 
head from one side to the other by raising 
head off surface enough to clear the nose. 
(Must be able to turn to both sides) 
 
2.  Brings hands to mouth: Lying on the back, 
the child brings either one or both hands to 
the mouth. 
 
3. Controls head at 45 degrees: Child lies on 
stomach, and lifts head to 45 degrees for at 
least 2 seconds. 
4. Controls head: Child supported at the hips in 
a sitting position can hold head up for at 
least 15 seconds 
 
5. Rolls from side to back: When placed on 
side, the child can roll onto back from both 
sides. This should be voluntary, and initiated 
by turning the head. 
Scoring:   1 month: 0 At Risk;  1-5 Satisfactory 
                 2 months: 0-2 At Risk; 3-5 Satisfactory 
2 months: 0-3 At Risk; 4-5 Satisfactory 
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FIRST VERSION 
4-5 months  
1. Holds head in midline (object of interest): 
Child holds head in midline for at least 5 
seconds. 
 
2. Controls head while prone: 45° (object of 
interest): Child maintains raised head at 
least 45° from exam surface for at least 2 
seconds. 
3. Sits with support: 30 seconds: Child sits 
with slight support for 30 seconds. 
 
4. Rolls from back to sides (object of 
interest): Child turns from back to both 
right and left sides. 
 
 
5. Grasps foot with hands: Child brings one 
or both feet up to hands (above the hips) 
and grasps a foot. 
Scoring: 
4 months: 0-2 At Risk; 3-5 Satisfactory 
5 months: 0-3 At Risk; 4-5 Satisfactory 
 
SECOND VERSION 
4-5 months 
1. Keeps head in midline: Child 
supported at the hips in a sitting   
position keeps head in midline for at 
least 10 seconds. 
2. Controls head at 45 degrees: Child 
lies on stomach, and lifts head to 45 
degrees for at least 10 seconds. 
The elbows must be in-line or in 
front of the shoulders. 
3. Sits with support: Child sits with 
support at the hips on a flat surface 
for at least 30 seconds. 
4. Rolls from back to sides. Child can 
do this to both sides. This should be 
voluntary, and initiated by lifting the 
head. 
5. Touches foot with hands: Child 
brings one or both feet up to         
hands to touch them 
Scoring: 
4 months: 0-2 At Risk; 3-5 Satisfactory 
5 months: 0-3 At Risk; 4-5 Satisfactory 
 
Figure 4.1 Items for the new section of the IGMST 
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After the appropriate changes were made following the discussion, the final version 
of the new section of the screening tool was ready to be compiled and the layout 
done. 
 
4.10 Compilation and Layout 
The completed IGMST (one to three months) (four to five months) was then compiled 
and an illustrator employed to insert appropriate images and ensure the layout 
matches the original IGMST. This section of the IGMST is now ready for further 
validity and reliability testing in future studies.  
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CHAPTER FIVE 
5 DISCUSSION 
The results of this study will be discussed in this chapter. The outcomes will be 
discussed as well as the data collected. Suggestions for future research will be given. 
 
The original IGMST was developed to screen for gross motor delay in infants 
between six and eighteen months. The new section of the tool was developed to 
screen for gross motor delay in infants from one month to five months. This will allow 
for earlier identification of infants with gross motor delay.  
 
Gross motor delay has been shown to be indicative of cognitive delay (including 
cognition, memory and processing speed) as the child gets older (Piek et al, 2008). 
Preschool age children receiving cART have been shown to be at risk for 
developmental delay across several developmental facets (Potterton et al, 2016). 
Early identification of gross motor delay allows for prompt referral for comprehensive 
assessments and access to early intervention services if needed. This addition to the 
screening tool is important as it allows for early identification of infants. Early referral 
and therapeutic intervention will give the infants experiencing delay the best possible 
outcome. As life expectancy of babies with medically managed HIV is increasing, this 
population is now likely to reach adulthood. They must be managed in all aspects 
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including neurodevelopment. This will give them the best quality of life in infancy and 
going into adulthood. 
 
The screening tool is easily accessible and reproducible. It can be administer without 
and specific training. This makes it a valuable resource in busy South African HIV 
clinics where time and staff are limited. 
 
5.1 Identification of Appropriate Items 
One of the objectives of the study was to identify gross motor items from the BSID III 
which were suitable for inclusion in the new section of the IGMST to include infants 
from one month to five months. This process will be discussed below:  
 
5.1.1 Selection of items from the BSID III 
The BSID III is a developmental assessment tool. It is used on infants and young 
children aged between one and forty-two months, and is administered on an 
individual basis. It is used to assess infants who may be presenting with 
developmental delay. The BSID III is reliable and valid, and is predictive of later 
developmental outcome (Bayley, 2006). The BSID III is considered the gold standard 
in infant development (Harris et al, 2005; Tieman et al, 2005). Its use on typical black 
African infants (0-18 months) in Johannesburg, who have socioeconomic 
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backgrounds similar to the study population, has been studied and it was found to be 
appropriate (Rademeyer, 2010; Brown, 2009).  
 
In this study, the BSID III was the starting point for the selection of items used to 
develop the new section of the IGMST. As this tool is considered the gold standard in 
infant development, and has proven validity, it was appropriate to begin the process 
of screening development using this tool.  
 
In addition, gross motor function is a set of skills that are achieved by all typically 
developing infants, making it universal. There is a limited number of items that can be 
assessed when examining gross motor function, especially in infants, this leads to 
similar items being used in a range of developmental assessment tools (Harris et al, 
2003; Aylward, 1995; Frankenburg et al, 1992; Piper et al, 1992).  
 
5.2 Requirements of the New Section of a Screening Tool  
Chapter two outlined the requirements for a screening tool in a resource-poor setting. 
It should identify those children who are experiencing developmental problems in 
order for them to be referred for additional assessment. The tool should be sensitive 
enough to distinguish between children who have developmental delay, and those 
who do not. Time-constraints should be considered. It should be quick and easy to 
administer, both to reduce the time taken for the assessor to get through a large 
volume of patients, but also to reduce the assessment time for a young child. Specific 
62 
  
training on administration of the tool should not be required. Nurses or counsellors 
could administer it, if need be. Budget should be taken into consideration. The tool 
should be inexpensive and should not require any specialised equipment or forms 
(Kammerer et al, 2013; Hilburn et al, 2011). 
 
South African HIV clinics are busy and experience many challenges. It is, therefore, 
important that the new section of the screening tool follow the guidelines above. 
 
The new section of the screening tool consists of two age bands (one to three 
months and four to five months). Each age band has five items that can be either 
achieved or not achieved. Along with this is the scoring. The tool is quick and simple 
to use and does not require specific training. Once further validity and reliability 
testing is completed, it will be uploaded along with the original IGMST, and will be 
available for free access online. It can also be freely distributed and copied which 
makes it an inexpensive tool. It also does not require any specialised equipment. 
The layout of the screening tool was based on the format and layout of the original 
version of the IGMST. This tool has been available since July 2011 for free download 
(Hilburn et al, 2011).   
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5.3 Single Domain Screening Test 
As outlined in Chapter Two, developmental assessments can either focus on a single 
domain or include numerous domains (Sabanathan et al, 2015; Kammerer et al, 
2013). The original IGMST used gross motor delay to identify infants at risk of global 
neurodevelopmental delay (Hilburn et al, 2011). 
 
5.3.1 Gross motor delay as an early identifier of global delay 
Gross motor items were chosen to make up the items of the new section of the 
IGMST. Numerous studies have demonstrated the existence of motor delay in infants 
infected with HIV (Laughton et al, 2012; Hilburn et al, 2011; Shead et al, 2010; 
Potterton et al, 2009; Van Rie et al, 2009; Abubakar et al, 2008; McGrath et al, 
2006). It has been shown that gross motor delay can be seen as early as four 
months (Whitehead et al, 2014). It has also been suggested that gross motor delay is 
the first indicator of global neurodevelopmental delay (Noritz et al, 2013). Testing for 
a single domain (gross motor) will likely identify an infant who is experiencing global 
delay now, or who may have global neurodevelopmental delay in the future. 
 
The new section of the IGMST will screen a single developmental domain (namely, 
gross motor) to identify infants who require a global neurodevelopmental assessment 
which may indicate a global neurodevelopmental delay. 
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5.4 Screening Tool Development 
The development of a screening tool was discussed in more detail in 2.9. According 
to the literature there are various means of screening tool development. 
The original IGMST was developed by analysing the available literature. Items were 
taken from an existing tool, namely the BSID III. Expert opinion was also used to 
formulate the items (Hilburn et al, 2011).  
 
Another locally developed screening tool, the RCWMST, was developed in 2014 to 
screen for nuerodevelopmental delay in infants with HIV. This tool adapted items 
from the Western Cape Developmental Screening Tool, the Denver Developmental 
Tools and the Molteno Adapted Scales. Clinical experience was also used to form 
the screening tool (Boyede et al, 2015).  
 
International tools such as the HINT (Harris et al, 2003) and Malawian 
Developmental Assessment Tool (Gladstone et al, 2008), have also sucessfully 
adapted items from exisiting tools to form a stand-alone tool. 
 
The process followed in the creation of the original IGMST produced a screening tool 
with excellent statistical properties. These methods are similar to the development of 
other local and international tools. The success of this original IGMST warrants 
replicating the methods to create an addition to the tool. 
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5.5 Age Band One to Three Months 
Initially, the study aimed to extend the IGMST from birth to five months, however, 
when the sample was analysed, the youngest infant was 2.0 months old. From the 
sample available, the age band could not be extended from birth. The evaluation of 
neonates is complex, this is explained in more detail in 5.5.1. It was, therefore, 
decided to exclude the first month due to the technical skill involved.  
 
5.5.1 Evaluation of neonates 
The evaluation of neonates primarily consists of eliciting responses to specific stimuli 
or handling techniques. This evaluation of reflexes and analysis of the movements 
repertoire requires specific training of professionals (Majnemer & Snider, 2005).  
Prechtl’s Assessment of General Movements is a frequently used method of 
assessing the integrity of the young nervous system. When used by a trained 
professional they are 83% in agreement (Valentin et al, 2005). General Movement 
(GM) assessment have been shown to be predictive of later scores on the BSID 
(those having atypical GM assessments scored poorly on the BSID) (Kodric et al, 
2010). 
 
GMs are a set of spontaneous movements shown by the young infant. They involve 
whole body movements and sequences, and an individual, specifically trained to do 
so, can analyse the quality of these movements. A child with an impaired nervous 
system has changes in the quality of their GMs. To perform these assessments 
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specific basic and advanced training must be done. Doctors or therapists usually 
undergo this training (Einspieler & Prechtl, 2005). 
 
Identification of early neurodevelopmental delay is difficult, and to be effective may 
rely on specific identification of the quality of movement done by profesionals with 
intensive training. According to the requirements for the screening tool (as outlined in 
5.2) the first month of life would be very difficult to include successfully. 
 
For this reason it was decided to not include the first month of life in this screening 
tool as it would be too difficult for individuals without specific training to assess these 
early movements.  
 
5.5.2 Overlap of fine and gross motor skills 
During the selection of items the second item, of the one to three month age band, 
was selected from the fine motor section of the BSID III. The item ‘brings hands to 
mouth’ was deemed to fit the criteria of a gross motor item. The movement involves 
whole limb movement which fits the criteria for inclusion in a gross motor screening 
tool. It was specified that two items in the age band should be completed by ≥70% of 
the infants, an additional two by 30% - 69% of the infants and one item completed by 
≤29%. In the age band one to three months, items one and three had 72% of infants 
completing this activity. Items two and four were completed by 68% of infants and 
item five completed by 28% of the infants. This selection ensured that the most 
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advanced infants were able to do all the selected items, while those experiencing 
neurodevelopmental delay scored as ‘At Risk’ and were identified for further 
assessment. This age band satisfies the criteria set for the items. In the second part 
of the study the item, ‘brings hands to mouth’, was accepted by 100% of the panel 
once wording had been adjusted. 
 
5.6 Scoring of the New Section of the IGMST 
For consistency, two scoring groups were used, as was done in the original IGMST. 
This also makes a decision based on the score easier. These categories are “At-risk” 
and “Satisfactory” (Hilburn et al, 2011). 
The final scoring is shown in the table 5.1 below: 
Table 5.1  Final Scoring 
Age Score to be obtained to be considered 
‘Satisfactory’ 
Score to be obtained to be 
considered  ‘At-Risk’ 
1 month 1-5 0 
2 months 3-5 0-2 
3 months 4-5 0-3 
4 months 3-5 0-2 
5 months 4-5 0-3 
 
As outlined in chapter three; scoring was determined according to the following: the 
oldest infants should be able to obtain credit for most/all items to be competent. The 
younger infants should have been able to obtain one
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competent. These guidelines were followed by Hilburn et al. (2011) in order to 
successfully create the original IGMST. 
 
5.7 Statistical Testing of the Items  
In this study, Pearson’s correlation coefficient was calculated in order to determine 
the relationship between the scores of the original BSID III scores and the reduced 
selection of items to be included in the IGMST. This was done in the initial 
development prior to presenting it to the expert panel. Pearson’s correlation has been 
used successfully to measure concurrent validity during the development of the 
Harris Infant Neuromotor Test (HINT) (Harris & Daniels, 1996), BINS (Aylward, 1995) 
and the AIMS (Piper et al, 1992). 
 
There were no reported values for Pearson’s correlation coefficient at this point in 
tool development on the above-mentioned tools. 
 
The Pearson’s correlation coefficient is interpreted as presented in Table 5.2 below 
(Jogi et al, 2011). 
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Table 5.2 Interpretation of the Pearson’s correlation coefficient (r) 
R value Interpretation 
0.90 - 1.0  Excellent 
0.70 – 0.89 Good 
0.40 – 0.69 Modest 
0.20 – 0.39 Low 
<0.20 Slight 
 
The minimally acceptable level for Pearson’s correlation co-efficient is 0.6 (Palisano 
et al, 2008; Meyer, 1974). 
 
The study aimed for a good correlation between the new section of the IGMST 
(Pearson’s correlation ≥0.7) and the scores achieved in gross motor section of the 
BSID III.  The age band one to three months achieved r= 0.68 (p=0.003). The one to 
three age band had a modest correlation. Although it does not satisfy the initial goal, 
it was very close to 0.7 and well above the 0.6 minimally accepted level (Palisano et 
al, 2008; Meyer, 1974). In addition the p value indicates that this is a significant 
correlation. The four to five age band had a Pearson’s correlation of 0.71 (p=0.0009). 
This is a good correlation and satisfied the initial goal for the screening tool, 
p=0.0009 indicates a significant correlation. The one to three month age band scored 
lower on the Pearson’s correlation, it however had a greater percentage (84%) of 
children who score the same on both tests than the four to five month age band 
(83%).  
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Pearson’s correlation was used to assess the concurrent validity in the development 
of the Harris Infant Neuromotor Test (HINT). This study found a Pearson’s correlation 
of r= - 0.89 (good correlation) between the motor scale of Bayley Scales of Infant 
development (2nd version) and the HINT and in the mental scale of BSID II r= -0.73 
(good correlation) (Harris & Daniels, 2001).  
 
In a Columbian study to develop and validate a scale for assessing the difficulties of 
daily care of children with severe cerebral palsy, Pearson’s correlation coefficient of 
0.71 (good correlation) was obtained when compared to the Gross Motor Function 
Classification System (GMFCS) (Carreno-Mora et al, 2015). 
 
Both the studies described above, reported a good Pearson’s correlation during the 
development of tools. This study achieved a good correlation (r=0.71; p=0.0009) for 
the four to five month age band and a modest correlation (r=0.68; p=0.003) for the 
one to three month age band. This is, however, very close to a good correlation and 
84% of the infants achieved the same score on both tests. This is also above the 
minimally acceptable level of 0.60  (Meyer, 1974; Palisano, 1986). When compared 
to the correlations achieved in other screening tools; the results achieved can be 
interpreted as acceptable.  
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5.8 Content Validity 
Validity is a measure of whether or not a tool measures what it is intended to. Validity 
encompasses content, criterion-related and construct validity. This study examined 
the content validity of the new section of the IGMST. Content validity specifically 
looks at whether the items in the tool are relevant to what they are intending to 
measure (Lynn, 1986).  
 
Establishing content validity is the first step in examining the validity of a new tool 
(McEwan et al, 2003). The same method of establishing content validity was done as 
in Hilburn et al. (2011). This was done using a panel of experts who obtained 
consensus on each item and commented on whether it was an appropriate tool or not 
(Harris & Daniels, 1996). 
 
Content validity can be considered a matter of expert judgement. There should be 
two phases, namely, careful development and expert assessment (Lynn, 1986). For 
development of a screening tool, there should first be identification of which domain 
is being assessed.  For the development of the new items of the IGMST, gross motor 
items were chosen from the BSID III. Secondly, item generation should be 
completed. The items chosen from the gross motor section of the BSID III would 
assess gross motor performance.  As discussed earlier in this chapter, the BSID III is 
considered the gold standard in infant development and has undergone thorough 
testing. The motor items selected from the BSID III are appropriate for inclusion in a 
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gross motor screening tool. This was completed in the development of the new 
section of the IGMST. 
 
Following this, the items must go through judgement by experts in the field of 
paediatrics. In this study a modified NGT was used to determine the content validity 
of the new section of the screening tool. It was shown to be a reliable method to 
establish content validity (Dobbie et al, 2004; Hyrkas et al, 2003). 
 
The NGT has successfully been used to establish content validity in development of 
the original IGMST. In this case, after appropriate changes, there was 100% 
agreement (Hilburn et al, 2011). A NGT was used sucessfully to establish the content 
validity of the original version of the GMFCS and the expanded and revised version 
of the GMFCS. In both of these studies 80% consenus was also used to establish 
agreement (Palisano et al, 2008; Palisano et al, 1997). The new section of the tool 
went through the appropriate steps in establishing content validity. 
 
As discussed in chapter four, this study had an expert panel consisting of five experts 
in the field of paediatrics. They were asked to examine and comment on five different 
questions relating to the content of new section of the screening tool.  
 
The concerns of the participants were discussed, and appropriate changes made to 
the tool. Once the appropriate changes had been made, there was 100% consensus 
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on all questions raised. Literature states that in order to reach agreement during a 
NGT discussion, 80% consensus must be reached (Potter et al, 2004). Having 100% 
agreement for all items meets this criteria.  
 
The expert panel was asked whether the age band two to three months could be 
expanded to one to three months without compromising the results of the tool. This 
was agreed upon by 100% of the expert panel.  
 
During the development of the HINT a group of experts was used to examine the 
content validity of the tool. When consensus was less than 80% revisions were made 
prior to the further validation of the tool. These revisions included changes to the 
wording of items and background information (Harris & Daniels, 1996). 
 
Changes were made at this point in the development of the original version of the 
IGMST. There were changes to items themselves, as well as the wording of items 
(Hilburn et al, 2011). 
 
5.9 Limitations 
• The available data sets did not include infants younger than 2.0 months. 
Expert opinion was used to expand the age band to one to three months, but 
the tool cannot be used on infants in the first month of life. 
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• The tool, as it stands, needs to undergo further validity and reliability testing 
before it can be used clinically. 
• The tool has only been standardised for use in infants with HIV. 
 
5.10 Implications of the Study 
• As access to cART increases, there is an increase in children living with HIV. 
These children have been shown to be at risk of severe neurodevelopmental 
delay. Once this tool has undergone further validity and reliability testing, it will 
be able to identify those infants at risk of neurodevelopmental delay and 
facilitate early referral of those infants a risk of delay.  
• The IGMST screens for gross motor delay. Gross motor function has been 
shown be the most affected developmental domain in infants with HIV. It has 
also been shown to be a predictor of global neurodevelopmental delay. Once 
infants are identified at risk of delay on this screening tool, they can undergo a 
full neurodevelopmental assessment which will test language and cognitive 
domains.  
 
5.11 Recommendations for Further Research 
5.11.1 Validity and reliability testing 
The new section of the IGMST has been developed during the course of this study. It 
has undergone preliminary testing. Before it can be used to test for developmental 
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delay in infants with HIV, it must undergo further validity and reliability testing. 
Criterion validity and concurrent validity must be established.  
 
The criteria for screening tool in a resource poor setting were outlined earlier in this 
chapter. After undergoing further testing, it will be known whether the tool properly 
identifies those who are experiencing delay and those who are not. 
 
Screening tests must also be tested to give information on the sensitivity, specificity, 
Positive Predictive Value and Negative Predictive Value. Further testing to establish 
these values should be undertaken to provide users of this test with more information 
on how it functions. 
 
Reliability testing should also be undertaken, this must include inter-rater reliability, 
test-retest reliability as well as intra-rater reliability. 
 
5.11.2 Standardisation of the IGMST in other high risk populations    
The original Infant Gross Motor Screening Test, and the new section created during 
this study, was developed to screen for gross motor delay in infants with HIV. The 
tool is standardised for this population. Standardisation testing on typically 
developing children as well as other high-risk populations (such as premature infants) 
should be done. 
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CHAPTER SIX 
6 CONCLUSIONS 
With early infant diagnosis of HIV and the improved access to cART, there is an 
increasing population of infants with HIV living into their childhood and adolescent 
years. These infants are at risk of neurodevelopmental delay. The key to offering 
appropriate therapeutic intervention in these cases is early identification of 
neurodevelopmental delay. Gross motor skills have been found to be consistently 
delayed in infants with HIV. In addition, gross motor skills have been shown to be 
predictive of global neurodevelopmental delay. Early gross motor screening, as in the 
IGMST, will allow for early referral for global neurodevelopmental assessments. 
 
To our knowledge, this is the first gross motor screening tool to be developed for 
infants with HIV from one month to five months. With this addition to the original 
IGMST, the tool as a whole, provides a way to screening for gross motor delay from 
one month to eighteen months. 
 
This study has created the new section of the screening tool by taking items from the 
motor section of the BSID III. Statistical testing of the new age bands was significant. 
The one to three month age band achieved a modest Pearson’s correlation of r=0.68 
(p=0.003). The four to five month age band achieved a good Pearson’s correlation of 
r=0.71 (p=0.009). These items have undergone content validity testing through a 
modified nominal group technique. The response of the panel was favourable. 
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The tool is now ready for further validity and reliability testing before it can be used in 
the clinical setting. The new age bands for the IGMST are shown in Figure 6.1 below: 
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   APPENDIX VI: EXAMPLE OF DATA CARPTURING FOR ITEM ANALYSIS 
 
 
  
Age Scaled Score Gross 1 Gross 2 Gross 3 Gross 4 Gross 5 Gross 6 Gross 7 Gross 8 Gross 9 Gross 10 Gross 11 Gross 12 Gross 13 Gross 14
5.04 4 55 1 1 1 1 1 0 1 0 1 1 1 1 0 0
5.17 2 49 1 1 1 1 1 0 1 0 1 1 0 1 0 1
2 2 2 2 2 0 2 0 2 2 1 2 0 1
100% 100% 100% 100% 100% 0% 100% 0% 100% 100% 50% 100% 0% 50%
4.02 5 76 0 0 1 1 1 1 1 1 0 1 0 1 0 0
4.08 6 77 1 1 1 1 1 1 1 0 0 1 0 1 0 0
5.12 6 70 1 1 1 1 1 1 1 1 1 1 1 1 0 0
5.19 6 70 1 1 1 1 1 1 1 1 1 1 1 1 1 1
5.28 6 61 1 1 1 1 1 1 1 1 1 1 1 1 1 1
4 4 5 5 5 5 5 4 3 5 3 5 2 2
80% 80% 100% 100% 100% 100% 100% 80% 60% 100% 60% 100% 40% 40%
4.07 10 88 1 1 1 1 1 1 1 1 1 1 1 1 1 1
4.11 10 82 1 1 1 1 1 1 1 1 1 1 1 1 1 1
4.04 12 100 1 1 1 1 1 1 1 0 1 1 1 1 0 1
4.07 8 107 1 1 1 1 1 1 1 1 1 1 1 1 1 0
4.02 11 91 1 1 1 1 1 1 1 1 1 1 1 1 1 1
4.09 9 85 1 1 1 1 1 1 1 1 1 1 1 1 1 1
4.09 11 112 1 1 1 1 1 1 1 1 1 1 1 1 1 1
4.0 11 103 1 1 1 1 1 1 1 1 1 1 1 1 1 1
5.27 12 110 1 1 1 1 1 1 1 1 1 1 1 1 1 1
5.19 11 107 1 1 1 1 1 1 1 1 1 1 1 1 1 1
5.02 9 91 1 1 1 1 1 1 1 1 1 1 1 1 1 1
11 11 11 11 11 11 11 10 11 11 11 11 10 10
100% 100% 100% 100% 100% 100% 100% 91% 100% 100% 100% 100% 91% 91%
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APPENDIX VIII: INFORMED CONSENT 
 
Informed Consent 
 
If you would like to take part in this panel discussion, please sign below 
I, __________________________________________________________, 
agree to take part in this study. I understand that I may withdraw from the study at any 
time. I have read the information sheet provided. I understand that notes on the discussion 
will be taken and securely stored, but that there is no guarantee of confidentiality for the 
notes. 
 
Signed: ________________________ Date: ________________________________ 
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